|Free Dividend Report|
|Stock Splits Calendar|
|ADMP Stock Split History|
|Preferred Stock Newsletter|
|ADMP Options Chain|
|Stock Message Boards|
Adamis Pharmaceuticals (ADMP) has 1 split in our ADMP split history database. The split for ADMP took place on December 13, 2013. This was a 1 for 17 reverse split, meaning for each 17 shares of ADMP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 58.8235294117647 share position following the split.
When a company such as Adamis Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ADMP split history from start to finish, an original position size of 1000 shares would have turned into 58.8235294117647 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamis Pharmaceuticals shares, starting with a $10,000 purchase of ADMP, presented on a split-history-adjusted basis factoring in the complete ADMP split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-15.78%|
|About Adamis Pharmaceuticals|
|Adamis Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. Co.'s products and product candidates include: Symjepi (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; Symjepi (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis for patients weighing 33-65 pounds; a naloxone injection product candidate (APC-6000) for the treatment of opioid overdose; a Beclomethasone metered dose inhaler product candidate (APC-1000) for the treatment of asthma; and among others. According to our ADMP split history records, Adamis Pharmaceuticals has had 1 split.|
|ADMP Split History Table|
|12/13/2013||1 for 17|
|Healthcare Stock Splits|
|ADMP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ADMP shares outstanding history